Summary of findings 4. Etanercept compared with placebo for hidradenitis suppurativa.

Etanercept compared with placebo for hidradenitis suppurativa
Patient or population: participants with hidradenitis suppurativa Settings: hospital‐based Intervention: etanercept Comparison: placebo
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk
	Placebo	Etanercept
Dermatology Life Quality Index Follow‐up: 12 weeks	‐	No significant difference between the 2 groups (P = 0.12, Mantel‐Haenszel test)	‐	17 (1 study)	⊕⊕⊕⊝ moderate¹	‐
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

¹Downgraded one level for imprecision due to a small number of participants in only a single study.